SCHEMBL1099296

SCHEMBL1099296

Cc1ccc(NC(=O)N2C=CC(=O)C[C@H]2c2ccc(F)cc2)cc1C

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 8/20 0.66
CACNA1H O95180 1/20 0.47
MAPT P10636 3/20 0.45
CRHBP P24387 1/20 0.45
CRHR2 Q13324 1/20 0.45
KDM4E B2RXH2 1/20 0.44
ALOX12 P18054 1/20 0.44
POLB P06746 1/20 0.43
HPGD P15428 1/20 0.43
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
TP53 P04637 2/20 0.43
EGFR P00533 1/20 0.42
NFKB1 P19838 1/20 0.40
HTT P42858 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1100305 0.89 P2RX7 (0.74) P2RX7CACNA1HMAPTCRHBPCRHR2
SCHEMBL1100619 0.88 P2RX7 (0.63) P2RX7CACNA1HMAPTHPGDNPC1
SCHEMBL1099849 0.87 P2RX7 (0.65) P2RX7CACNA1HMAPTKDM4EHPGD
SCHEMBL1099787 0.86 P2RX7 (0.62) P2RX7CACNA1HMAPTKDM4EHPGD
SCHEMBL1101227 0.84 P2RX7 (0.71) P2RX7CACNA1HMAPTCRHBPCRHR2
SCHEMBL1100044 0.84 P2RX7 (0.74) P2RX7MAPTCRHBPCRHR2HTT
SCHEMBL1098967 0.84 P2RX7 (0.73) P2RX7CACNA1HPOLBHPGDRAB9A
SCHEMBL1099968 0.83 P2RX7 (0.79) P2RX7CACNA1HHPGDEGFR
SCHEMBL1100972 0.83 P2RX7 (0.56) P2RX7CACNA1HHPGD
SCHEMBL1100504 0.83 P2RX7 (0.60) P2RX7CACNA1HKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2393781-B1 DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS HOFFMANN LA ROCHE (CH) 2014-03-12 EP disclosed
US-8153809-B2 Dihydropyridone ureas as P2X7 modulators ROCHE PALO ALTO LLC (US) 2012-04-10 US disclosed
US-8153809-B2 Dihydropyridone ureas as P2X7 modulators ROCHE PALO ALTO LLC (US) 2012-04-10 US disclosed
US-8153809-B2 Dihydropyridone ureas as P2X7 modulators ROCHE PALO ALTO LLC (US) 2012-04-10 US disclosed
WO-2010072599-A1 DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS F. HOFFMANN-LA ROCHE AG (CH) 2010-07-01 WO disclosed
US-20100160388-A1 DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS ROCHE PALO ALTO LLC 2010-06-24 US disclosed
US-20100160388-A1 DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS ROCHE PALO ALTO LLC 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160388-A1 DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS P2RY1, P2RX1, P2RX3 P2RX7 5/4885CACNA1H 570/4885MAPT 1035/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.